{
  "source": "PA-Notification-Caplyta.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1314-5\nProgram Prior Authorization/Notification\nMedication Caplyta® (lumateperone)\nP&T Approval Date 5/2020, 8/2021, 3/2022, 3/2023, 3/2024, 4/2025\nEffective Date 7/1/2025\n1. Background:\nCaplyta is FDA approved for the treatment of schizophrenia and for depressive episodes associated\nwith bipolar I or II disorder as monotherapy and as adjunctive therapy with lithium or valproate in\nadults. Members will be required to meet the coverage criteria below.\n2. Coverage Criteriaa:\nA. Initial Authorization\na. Caplyta will be approved based on one of the following criteria:\n(1) Diagnosis of schizophrenia\n(2) Diagnosis of depressive episodes associated with bipolar I or II disorder (bipolar depression)\nAuthorization will be issued for 12 months.\nB. Reauthorization\na. Caplyta will be approved for continuation of therapy based on the following criterion:\n(1) Documentation of a positive clinical response to therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit plan\ncoverage may also impact coverage criteria. Other policies and utilization management programs may\napply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Step Therapy and Supply limits may be in place.\n4. References:\n1. Caplyta [package insert]. New York, NY: Intra-Cellular Therapies, Inc. June 2023.\n© 2025 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification - Caplyta (lumateperone)\nChange Control\n5/2020 New program.\n8/2021 No changes.\n3/2022 Updated to include coverage for depressive episodes associated with\nbipolar disorder due to new labeling.\n3/2023 Annual revi",
    "(lumateperone)\nChange Control\n5/2020 New program.\n8/2021 No changes.\n3/2022 Updated to include coverage for depressive episodes associated with\nbipolar disorder due to new labeling.\n3/2023 Annual review. Updated reference. Added state mandate language.\n3/2024 Annual review. Updated reference.\n4/2025 Annual review with no changes.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}